Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200093 · ClinicalTrials.gov registry record · Phase 4
Oral Vancomycin for Preventing Clostridium Difficile Recurrence
A Phase 4 study, sponsored by Rochester General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03200093 is a Phase 4 study that was terminated before completion, run by Rochester General Hospital. The registered enrollment target is 65 participants.
The verdict
NCT03200093, a Phase 4 study, was terminated before completion, sponsored by Rochester General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.
Interventions
- DRUG Placebo
- DRUG Oral Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03200093
The ClinicalTrials.gov registry entry for NCT03200093 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rochester General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03200093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03200093 about?
NCT03200093 is a clinical study titled "Oral Vancomycin for Preventing Clostridium Difficile Recurrence". This study evaluates the role of oral vancomycin in the prevention of recurrent Clostridium difficile for hospitalized patients receiving systemic antibiotic therapy. Half of participants will receive oral vancomycin daily, while the other half will receive a placebo.
What is the current status of trial NCT03200093?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2017-06-08. Estimated completion is 2021-04-22.
What interventions are being tested in trial NCT03200093?
The interventions under investigation include: Placebo (DRUG), Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03200093?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.